


The 19th Andrew H. Weinberg Symposium

“Drug Development for Pediatric Cancers-Turning Challenges into Opportunities: A View from the Other Side”

Speaker: Dr. Gregory H. Reaman, Associate Director, Office of Hematology and Oncology Drug Products, United States Food and Drug Administration

Report by Steven DuBois, MD, MS Director, Experimental Therapeutics, Pediatric Oncology, Dana-Faber Cancer Institute



On October 29, the Weinberg Symposium committee welcomed Dr. Greg Reaman to Dana-Farber to deliver the 19th Annual Weinberg Symposium. Dr. Reaman is currently the Associate Director in the Office of Hematology and Oncology Drug Products at the US Food and Drug Administration (FDA). He is also the former group chair of the Children’s Oncology Group (COG), the only cooperative group in the United States dedicated to clinical trials for pediatric cancer.

Dr. Reaman’s lecture provided a summary of the current state of childhood cancer outcomes. He then presented a compelling overview of the need for federal incentives to motivate clinical trials in pediatric indications. The majority of his presentation focused on the complex federal laws intended to ensure that promising new medicines are also evaluated in children. These laws include the Best Pharmaceuticals for Children Act (BPCA), the Pediatric Research Equity Act (PREA), and the FDA Safety and Innovation Act (FDASIA). For additional details, the reader is encouraged to view a video of Dr. Reaman’s presentation at this link:

<http://video.dfcionline.org/accordent/2015WeinbergSymposium102915>

In addition to his lecture, Dr. Reaman provided his insights in several smaller meetings throughout his visit. He presented a seminar to oncology fellows and junior faculty training in clinical research. He also met with a number of senior faculty members leading clinical trials.

**The 20th Annual Andrew H. Weinberg Symposium will be held
Wednesday, September 28, 2016**

Mignon Loh, MD Professor of Clinical Pediatrics, Chief, Division of Pediatric Hematology/Oncology, UCSF School of Medicine will be the speaker.

Dr. Loh's research is focused on clinical-translational studies in pediatric leukemia. Her interests are split between two diseases, juvenile myelomonocytic leukemia (JMML) and acute lymphoblastic leukemia (ALL). It broadly involves the identification, significance, and function of genetic mutations in pediatric leukemia.

Further information about the symposium will be in the September Nucleus.